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8, Feb. 2019.Granuloma annulare (GA) is a benign inflammatory dermatosis of unknown cause, of which generalised granuloma 
) is a subtype that tends to be resistant to treatment. Various antibiotics have been used to treat GGA, the most 
mbination therapy with rifampicin, ofloxacin and minocycline (ROM). This study aims to explore the efficacy of 
eating GGA, and whether antibiotics may be useful in children with GGA. 
 Methods: A systematic review of literature published from 1947 to 2017 was undertaken in order to evaluate the 
cs in treating GGA. Data on characteristics of children with GGA were extracted and eligible studies were then 
alysed. 
 hundred and ninety (790) potential studies were identified, of which 16 were eligible for inclusion in the final 
ese 16 studies, majority were case studies (n=9, 56.3%), with 2 case series (12.5%), 2 retrospective studies (12.5%) 
el prospective studies (18.8%). Main antibiotic treatments reported were either monthly combination therapy of 
xacin and minocycline (ROM), or monotherapy with dapsone or doxycycline. Out of a total of 158 patients with GA, 
.6%) were treated with antibiotics. Of the 72, 48.6% (n=35) of these patients had GGA while 4 were children; two 
h GGA), all of whom were treated with dapsone. 
here is paucity of evidence to support the use of antibiotics in the treatment of GGA in children. Although ROM 
ising results in adults, more studies are needed to validate these findings in children. 
anuloma annulare; generalised granuloma annulare; antibiotics; children; outcome.      
viations: Granuloma Annulare (GA); Generalised granuloma annulare (GGA); Rifampicin, ofloxacin and 
OM); Localised granuloma annulare (LGA); Perforating granuloma annulare (PGA); Subcutaneous granuloma 
); Patch granuloma annulare (PaGA); Medical subject headings (MeSH); Complete resolution (CR); Partial 
). 
 
a annulare (GA) is a benign, granulomatous dermatosis (Lukács et al., 2015) of unclear aetiology with 
in presentations (Thornsberry & English, 2013). It is usually asymptomatic, although skin lesions may sometimes 
tender (Steiner et al., 1985). The 3 most common variants of GA include localised granuloma annulare (LGA), 
nuloma annulare (GGA) and subcutaneous granuloma annulare (SGA), while rare variants include perforating 
ulare (PGA) (Cyr, 2006; Piette and Rosenbach, 2016).  
logical appearance of LGA is made up of foci of granulomatous inflammation and collagen alteration in the upper 
is (Brey et al., 2006). There is peripheral pallisading of infiltrates consisting of histiocytes, lymphocytes and 
t cells around the degenerative collagen bundles (Brey et al., 2006). LGA tends to occur in patients under the age 
g female and male patients in a 2:1 ratio; and accounts for majority of cases of GA, comprising 75% of GA 
Cyr, 2006).  It predominantly affects the dorsum of the hands or feet (Thornsberry and English, 2013) and 
lves spontaneously within 2 years (Cyr, 2006). It can be managed conservatively, although several therapeutic 
ng high-potency topical corticosteroids, intralesional injections of glucocorticoids or cryotherapy, have also been 
fective in its treatment (Lukács et al., 2015). 
her hand, although interstitial histiocytic infiltrate is also seen on histological examination in GGA, there is less 
en alteration (Brey et al., 2006). GGA is clinically characterised by the presence of 10 or more skin lesions or 
ular plaques, accounts for up to 15% of GA cases, and has a bimodal age distribution involving patients over 40 or 
nline: 3rd, July, 2019  
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under 10 years of age (Cyr, 2006; Thornsberry and English, 2013). It has a longer disease course than LGA (Cyr, 2006) and is 
more resistant to treatment (Lukács et al., 2015) in spite of its histological similarity with LGA. 
In PGA, the most common of the rare GA variants, skin papules, have a central crust or scale which may sometimes be 
umbilicated, whereas in SGA, deep dermal or subcutaneous nodules are observed (Cyr, 2006; Muhlbauer, 1980). Other rarer 
forms of GA will not be discussed within the remit of this review. 
While there remains interest in identifying effective therapeutic options for GGA for both symptomatic and cosmetic reasons, 
there is a lack of good quality evidence to support one form of treatment over another in GGA, with most of the current literature 
surrounding treatment of GGA consisting of case reports or case series or small retrospective studies (Thornsberry and English, 
2013). Examples of therapeutic options which have been reported include high-potency topical or systemic corticosteroids, 
immunosuppressants, and antibiotics. Various antibiotics have been proposed as potential therapy for GGA, the most recent being 
combination therapy with rifampicin, ofloxacin and minocycline (ROM)(Garg and Baveja, 2015) . This article aims to explore the 
use of antibiotics in treating GGA with focus on the paediatric GA sub-group. 
Material and Methods 
Search strategy  
A search strategy was designed to identify original articles (including case reports and observational studies) reporting the 
use of antibiotics in the management of granuloma annulare. MEDLINE, EMBASE and Cochrane library were searched from 
August 1947 to July 2017. Papers using the ISI web of knowledge were also searched, to identify relevant articles and conference 
proceedings. The medical subject headings (MeSH) terms used included ‘‘granuloma annulare”, ‘‘generalised granuloma 
annulare”, ‘‘antibiotics”, “children” and ‘‘child”. Additional searches were also carried out with the individual antibiotic names 
generated from the initial search (dapsone, doxycycline, rifampicin, minocycline, ofloxacin, ROM). The full search strategies are 
shown in Appendix 1. Only studies published in English language and with full text availability were included in the review. In 
addition, reference lists of selected papers were screened to retrieve relevant studies.  
Study selection  
Studies were eligible for inclusion if they reported use of antibiotics in the management of granuloma annulare, with the 
intent of treating GGA in adults or children. The included studies were then further assessed for the efficacy of antibiotics in 
treating GGA and relevant data extracted on their use in the paediatric sub-group.  Granuloma annulare was defined as groups of 
flesh-coloured or erythematous papules arranged in an annular shape. Localised GA was defined as GA lesions, which were 
limited to a specific body area, most commonly the extremities. Generalised granuloma annulare was defined as the presence of 
10 or more GA lesions (Cyr, 2006). A clinical diagnosis was accepted for the different types of GA based on their clinical 
appearance. Histological confirmation of diagnosis was desirable but not obligatory if the authors had reported a clinical diagnosis 
of GA. 
Exclusion criteria were articles where full text was not available in English or where duplicate data was reported. This was 
done by assessing whether the articles were using the same or too similar data to come to their conclusions. In such cases, only the 
original article was used so as not to bias the results. Articles were also excluded if they did not address the use of antibiotics to 
treat GGA. Two of the authors of this study (G.C. and G.O.), working independently, screened the title and abstract of papers 
identified by the electronic searches, evaluating inclusion and exclusion criteria for all papers. Full articles of included 
publications were retrieved, where available, and each article was then independently reviewed for eligibility. Discrepancies were 
resolved by discussion with a third author (L.A).  
Quality assessment and data extraction  
Two reviewers (G.C. and G.O.) independently reviewed the methodological quality of included studies, comparability of 
case and cohorts, and outcomes. The explanatory variables extracted included: study design, country, description of study subjects, 
clinical presentation, antibiotics used, side effects and outcome of treatment. The study quality assessment was undertaken 
according to the Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement for the conduct and reporting 
of systematic reviews (Moher et al., and PRISMA Group, 2009). 
Data analysis 
Data from eligible studies were pooled for descriptive and qualitative analysis to provide an overview of the demographic 
distribution of adults and children with GA, the use and efficacy of antibiotics in treating GA, risk of disease recurrence after 
antibiotic use, and associated side effects. The response to antibiotics (whether partial or complete resolution was achieved) was 
assessed qualitatively from the data provided and accepted if described as such by the authors. We also descriptively compared 
these outcomes of interest in children versus adults where data was available. Results were then summarised in Table format.  
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Results 
Study characteristics 
Seven hundred and ninety potential studies were identified during the initial search, of which 229 were duplicates. Of the 
remaining 561 studies, 545 studies were excluded on the basis of title, abstracts and duplicate data (Figure 1). The 16 eligible 
studies (Boyd, 2012; Cheng et al., 2016; Duarte et al., 2009; Garg and Baveja, 2013; Garg and Baveja, 2015; Gualco et al.,, 2007; 
Kiremitci et al., 2006; Kovich and Burgin, 2005; Kozic and Webster, 2011; Mahmood et al.,, 2015; Marcus et al., 2009; 
Martín-Sáez et al., 2008; Saied et al., 1980; Simpson et al., 2014; Steiner et al., 1985; Yun et al., 2009) included in the final 
analysis were from USA (n=7, 43.8%), Europe (n=5, 31.3% – Turkey considered to be in Europe for purposes of this review), Asia 
(n=4, 25%), and none from South America or Africa. Majority were case studies (n=9, 56.3%), with 2 case series (12.5%), 2 
retrospective studies (12.5%) and 3 open-label prospective studies (18.8%). Main antibiotic treatments reported were monthly 
combination therapy with rifampicin 600mg, ofloxacin 400mg and minocycline 100mg (ROM), or monotherapy with dapsone or 
doxycycline. Of the open-label studies, 2 looked at ROM combination therapy (Garg and Baveja., 2015; Simpson et al., 2014) and 
one studied the use of dapsone in GGA (Steiner et al., 1985). Of these, one study (Simpson et al., 2014) did not state that patients 
had GGA and their selection criteria for treatment was patients with more than 5 GA lesions. It was, therefore, unclear how many 
patients in this study met the criteria for GGA according to the American definition of at least 10 lesions. Nevertheless, this article 
seemed to be targeting patients with disseminated GA and was, therefore, included under ‘Other/unknown GA subtypes’ of the 
summary table of study characteristics. Only 4 of the 16 studies reported GA in children (Cheng et al., 2016; Saied et al., 1980; 
Steiner et al., 1985; Yun et al., 2009).  
In addition, only 3 out of the 16 eligible studies reported recurrence/relapse of disease.This occurred between 1-3 months 
post-treatment in 2 articles and between 3 months and 10 years in 1 article. Two of the 16 articles reported treatment failure. The 
remaining 13 articles did not report recurrence or state that no recurrence had occurred either during their period of follow up – it 
was, therefore, not possible to draw any conclusions about disease recurrence or follow up period in those studies as this may not 
be long enough to allow for this outcome. Where reported, length of follow up varied from 4 weeks in one of the studies to 10 
years in another of the studies. Two of the 16 studies (Mahmood et al., 2015 and Simpson et al., 2014) reported progression of 
lesions after treatment. Most of the studies (87.5%, n=14/16) had a histopathological diagnosis of GA. A summary of the study 
design, study subjects, antibiotics used and outcome is presented in Tables 1 to 3. 
Figure 1: PRISMA flow diagram demonstrating identification and selection of eligible studies 
Records identified through database 
searching 
(n = 789)
Additional records identified through 
other sources 
(n =1)
Records after duplicates removed 
(n = 561) 
Records screened 
(n = 561) 
Records excluded (did not report 
about the use of antibiotics to 
treat generalised GA, no English 
full text or abstract available) 
(n = 544) 
Full-text articles assessed 
for eligibility 
(n =17) 
Full-text articles excluded 
(duplicate data) 
(n = 1) 
Studies included in 
qualitative synthesis  
(n = 16)
4 
Table 1:Description and Characteristics of GGA treated with antibiotics in the published studies that were included in the systematic review 
First 
author 
Year Country Study 
design 
No. of 
subjects 
receiving 
antibiotics 
Age Sex  
Histological 
confirmation 
of diagnosis 
Antibiotic Treatment 
duration 
Side effects Treatment 
outcome 
Prior treatment Post-antibioti
c treatment 
Garg 
(Garg & 
Baveja, 
2015)* 
2015 India Open label 
prospective 
trial 
5/6 48y-
53y 
F Yes ROM 4-8months - Complete 
resolution with 
post-inflammato
ry 
hyper-pigmentat
ion/ epidermal 
atrophy; no 
recurrence 
Anti-tuberculosis 
therapy, deflazacort 
pulse therapy, 
Clobetasol 
propionate 0.05% 
cream 
- 
Simpson 
(Simpson 
et al., 
2014) 
2014 USA Open-label 
prospective 
study 
See Table 3 ROM See Table 3
Mahmood 
(Mahmoo
d et al., 
2015) 
2015 USA Case report 1 64y F Yes ROM  6 months - 50% 
improvement at 
3 months then 
progression of 
lesions 
Topical/ 
intralesional 
corticosteroids 
Adalimumab 
Garg 
(Garg & 
Baveja, 
2013) 
2013 India Case report 1 52y F Yes ROM 5 months - Complete 
clearance after 5 
months with 
mild epidermal 
atrophy, no 
recurrence at 3 
months of 
follow-up 
- - 
Marcus 
(Marcus et 
al., 2009) 
2009 USA Case series 4/6 49y-
81y 
1M 
3F 
No ROM 3 months Improvement at 
3 months, 
complete 
clearance +/- 
residual 
hyper-pigmentat
ion at 3-4 
months 
Liquid nitrogen, 
pimecrolimus 
hydrocortisone 1%, 
clarithromycin, 
tacrolimus, 
fluticasone 
propionate, 
intralesional/ topical 
triamcinolone 
acetonide, excimer 
laser 
- 
Steiner 
(Steiner et 
1985 Austria Open-label 
prospective 
10/16 33y-
72y
4M 
6F 
Yes Dapsone 
100mg  
2-18 weeks Headache 
and 
4 Complete 
remission (CR) 
Cryotherapy, 
PUVA, topical 
- 
5 
al., 1985)* study weakness 
(5/16 
patients) 
resulting in 
dis-continua
tion of 
therapy in 2 
patients. 
3 partial 
response (PR) 
1 no response 
2 not evaluable 
All adults 
relapsed 
between 1-3 
months.  
steroids, retinoids 
Boyd 
(Boyd, 
2012) 
2012 USA Case report 1 40y F Yes Dapsone - - Failed treatment Topical steroids, 
hydroxychloroquine
, pioglitazone, 
acitretin  
Calcitriol 
Martín-Sá
ez 
(Martín-S
áez et al., 
2008)
2008 Spain Case report 1 72y F Yes Dapsone 
100mg OD 
15 months - Complete 
clearance 
Topical/oral 
steroids, PUVA, 
oral potassium 
iodide 
- 
Gualco 
(Gualco et 
al., 2007) 
2007 Italy Case report 1 73y F Yes Dapsone 
100mg 
(with 
prednisone 
25mg OD) 
Ongoing at 
time of 
report 
- Clearance of 
lesions 
Ceftriaxone - 
Kiremitci 
(Kiremitci 
et al., 
2006) 
2006 Turkey Case report 1 54y M Yes Dapsone 
200mg OD 
(with 
concurrent 
topical 
steroid) 
- - Clearance of 
majority of 
lesions with 
residual 
hyper/hypo-pig
mented 
areas/anetoderm
a 
PUVA 
Saied 
(Saied et 
al., 1980) 
1980 USA Case series 2 16y F Yes Dapsone 
100mg OD 
then 
Dapsone 
100mg 
alternate 
days 
2 weeks 
2 weeks 
- Complete 
clearance at 4 
weeks with 
slight residual 
hyper-pigmentat
ion, no relapse 
- - 
50y M Yes Dapsone 
200mg OD
then 
Dapsone 
100mg OD
4 weeks
-
- Clearance of 
GA lesions at 4 
weeks with 
residual 
post-inflammato
0.1% halcinonide 
cream, fluocinonide 
cream, 
flurandrenolide tape
-
6 
ry 
hyper-pigmentat
ion at 10month 
follow up
Cheng 
(Cheng et 
al., 2016) 
2016 Taiwan Retrospectiv
e study 
See Table 3 Dapsone See Table 3
Yun (Yun 
et al., 
2009) 
2009 Korea Retrospectiv
e study 
See Table 3 Dapsone See Table 3
Kozic 
(Kozic & 
Webster, 
2011) 
2011 USA Case report 1 50y F Yes Doxycyclin
e 100mg 
BD 
- - Ineffective Topical steroids, 
oral prednisone 
Pentoxifylline 
(ineffective), 
methotrexate 
(lost 
effectiveness), 
adalimumab 
Duarte 
(Duarte et 
al., 2009) 
2009 Portugal Case report 1 52y F Yes Doxycyclin
e 100mg 
OD 
10 weeks - Almost 
complete 
resolution, 
sustained at 1 
year 
Dapsone, pulsed 
light 
- 
Kovich 
(Kovich & 
Burgin, 
2005) 
2005 USA Case report 1 94y M Yes Doxycyclin
e 100mg 
BD 
3 months GI 
disturbance 
leading to 
dis-continua
tion of 
therapy 
Partial 
improvement 
Fluocinomide 
ointment 
Fluocinomide 
ointment 
*See Table 2 
USA=United States of America; y=years; m=months; F=female; M=male; ROM=rifampicin, ofloxacin and minocycline; CR=complete response, PR=partial response, 
PUVA=photochemotherapy with psoralen/UVA; mg=milligrams; OD= once daily; BD=twice daily; GI=gastrointestinal
7 
Table 2: Description and Characteristics of Localised GA treated with antibiotics reported in articles listed in Table 1 
First 
author 
Year Country Study design No. of 
subjects 
receiving 
antibiotics 
Age Sex Histological 
confirmation 
of diagnosis 
Antibiotic Treatment 
duration 
Side effects Treatment 
outcome 
Prior treatment Post-antibiot
ic treatment 
Garg (Garg 
& Baveja, 
2015)** 
2015 India Open label 
prospective 
trial 
1/6 55y F Yes ROM 8 months - Complete 
clearance 
with 
post-inflamm
atory 
hyper-pigmen
tation, no 
recurrence at 
12 month 
follow up 
Clobetasol 
propionate 0.05% 
cream 
- 
Marcus 
(Marcus et 
al., 2009)** 
2009 USA Case series 2/6 44y 1M 
1F 
No ROM 3 months Insomnia, 
body fluid 
discolouration 
Improvement 
at 3 months, 
complete 
clearance 
with residual 
hyper-pigmen
tation at 5 
months/post-i
nflammatory 
pigmentation 
Pimecrolimus 
hydrocortisone 
1%, 
desoximetasone, 
mometasone 
furoate, topical 
triamcinolone 
- 
Steiner 
(Steiner et 
al., 1985)** 
1985 Austria Open-label 
prospective 
study 
6/16 (1 10 
year old girl, 
5 adults)
10y, 
22y-
69y
4M 
2F 
Yes Dapsone 
100mg 
(adults)/ 
Dapsone 
50mg (child) 
6-18 weeks - 2CR, 4PR  
All adults 
relapsed 
between 1-3 
months.  
Remission 
sustained in 
10 year old 
girl. 
- - 
Cheng 
(Cheng et 
al., 2016) 
2016 Taiwan Retrospective 
study 
See Table 3 Dapsone See Table 3
**See Table 1 
USA=United States of America; y=years; m=months; F=female; M=male; ROM=rifampicin, ofloxacin and minocycline; CR=complete response, PR=partial response, 
PUVA=photochemotherapy with psoralen/UVA; mg=milligrams; OD= once daily; BD=twice daily; GI=gastrointestinal 
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Table 3: Description and Characteristics of other GA subtypes/treatment modalities reported in articles listed in Tables 1 and 2
Author Year Country Study design No. of 
subjects 
Age Sex GA subtype Treatments Treatment 
duration 
Side 
effects 
Treatment outcome 
Simpson 
(Simpson et 
al., 2014)
2014 USA Open-label 
prospective 
study
21 18y-75y 1M 
20F  
Not reported – 
all subjects had 
more than 5 
lesions; biopsy 
proven in 15 of 
21 subjects 
ROM 6 months - 10 subjects had at least 50% 
improvement in lesions, of which 3 had 
75% improvement and 1 had complete 
resolution. No response or worsening of 
existing lesions in 6 subjects. <50% 
improvement in the remainder (n=5)
Cheng 
(Cheng et 
al., 2016) 
2016 Taiwan Retrospective 
study 
44 2y-75y (16 
children, 28 
adults) 
23M 
21F 
16 generalised 
(13 adults, 3 
children) 
22 localised (14 
adults, 8 
children) 
2 perforating 
(both children) 
4 subcutaneous 
(1 adult, 3 
children) 
All biopsy 
proven 
Reported in 35/44 patients 
Dapsone: 5 adults (unclear how 
many generalised, how many 
localised GA) and both children 
with perforating GA, unclear if other 
children received dapsone 
Intralesional/topical steroids: 12 
adults (unclear how many 
generalised, how many localised 
GA), unclear how many children 
17 adults (13 generalised, 4 
localised) and 8 children (3 
generalised, 3 localised, 2 
perforating) received treatment in 
total 
No treatment: 5 adults (4 localised, 
1 s/c) and 5 children (2 localised, 3 
s/c) 
Not reported: 6 adults and 3 
children, all with localised GA 
- - Reported in 35/44 patients 
Adults receiving dapsone: 2/5 PR and 
3/5 CR 
Adults receiving intralesional/ topical 
steroids: 3/12 CR, 5/12 PR, 4/12 not in 
remission (CR or PR) 
PR/CR achieved in all 8 children who 
received treatment (of which at least 2 
with perforating GA received dapsone) 
No treatment: 4/5 good response 
(adults), 4/5 remission (children) 
Recurrence noted in 3 adults and 2 
children (GA subtype/treatment 
modality not stated); disease free 
interval 3m to 10y 
Yun (Yun 
et al., 2009) 
2009 Korea Retrospective 
study 
54 3m-84y 
(24 
children out 
of 54) 
29M 
25F 
Generalised; all 
biopsy proven 
5 dapsone 
13 topical steroids 
8 systemic steroids 
3 hydroxychloroquine 
2 PUVA 
2 cyclosporine 
2 isotretinoin 
19 not reported 
Unclear how many adults/children 
received each type of treatment 
- - Efficacy: 
Dapsone 2/5 
Topical steroids 10/13 
Systemic steroids 6/8 
Hydroxychloroquine 1/3 
PUVA 1/2 
Cyclosporine 1/2 
Isotretinoin ½ 
USA=United States of America; y=years; m=months; F=female; M=male; ROM=rifampicin, ofloxacin and minocycline; CR=complete response, PR=partial response, 
PUVA=photochemotherapy with psoralen/UVA; mg=milligrams; OD= once daily; BD=twice daily; GI=gastrointestinal 
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Antibiotic treatment in Granuloma Annulare 
A total of 158 patients of all ages in 16 studies were included in the final analysis (Table 1), of which 72 patients (45.6%) 
were treated with antibiotics. Of these 72 patients, there were 63 adults, 4 children, and 5 patients whose age could not be determined 
from the original articles. 
Patients with GGA constituted 48.6% of patients who received antibiotic therapy (n=35/72). Of the remaining patients, 9 had LGA 
(12.5%), 2 had PGA (2.8%) and the GA subtype was unknown in 26 patients (36.1%). Patient demographics and treatment 
modalities, including types of antibiotics used, are summarised in Tables 4 and 5. 
Table 4: Summary of the characteristics of included studies 
Characteristic Number (% of total) 
Total number of patients 158 
Gender 
Male 66 (41.8) 
Female 92 (58.2) 
Age 3months – 94 years  
Adults (>=18y) 116 (73.4) 
Children (0 to <18y) 42 (26.6) 
GA subtype 
Generalised 100 (63.3%) 
Localised 31 (19.6%) 
Perforating 2 (1.3%) 
Subcutaneous 4 (2.5%) 
Unknown 21 (13.3%) 
Treatment 
Antibiotics 72 (45.6%) 
Other treatments 42 (26.6%) 
No treatment 10 (6.3%) 
Unknown/not reported 34 (21.5%) 
Table 5: Types of antibiotic treatment given by subtype of GA. 
Antibiotic treatment (n=72) Generalised GA  Localised GA Perforating GA Unknown 
Dapsone only 19 (26.4%) 6 (8.3%) 2 (2.8%) 5 (6.9%) 
Dapsone with steroid 2 (2.8%)  0 (0%)  0 (0%) 0 (0%) 
Doxycycline 3 (4.2%)  0 (0%)  0 (0%) 0 (0%) 
ROM combination therapy 11(15.3%) 3 (4.2%)  0 (0%) 21 (29.2%) 
Type of antibiotic treatment given by subtype of GA. R, Rifampin; O, ofloxacin; M, minocycline; ACA, amoxicillin/clavulanic acid. 
Granuloma annulare in children (less than18 years old)
      Children made up 26.6% (n=42/158) of the subjects. Of these, only 9.5% (4/42) of children received antibiotic therapy. This 
constituted 5.6% (4/72) of the total number of patients who were treated with antibiotics (Figure 2). These consisted of 1 child with 
GGA, 1 child with LGA, and 2 children with PGA. All 4 children were treated with dapsone. A further 5 out of 42 children (11.9%) 
did not receive any treatment (2 had LGA and 3 had SGA). Treatment modalities in the remaining 33 children (78.6%) were not 
reported.  
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Treatment outcomes 
Outcomes of antibiotic treatment in adult patients (18 years old and above) 
From the data, 82.5% (52/63) of the adult patients had partial or complete response to antibiotic therapy, with the remaining 
17.5% (11/63) of adults having no response, disease progression or unevaluable treatment outcome in spite of antibiotics. Also, 4 
of the 5 adults (80%) receiving no treatment achieved spontaneous remission. Of the initial responses to treatment, disease 
relapse/recurrence was reported in 12 adults with GGA who received dapsone. A further 3 adults also had recurrence of disease; 
however, it was unclear from the original articles what treatment modality or GA subtype they had. 
Outcomes of antibiotic treatment in children (less than18 years old) 
All 4 children treated with antibiotics achieved partial to complete remission. This was sustained in the 2 children with GGA 
and LGA respectively. Four of the five children who received no treatment (80%) also achieved remission spontaneously. Disease 
recurrence was reported in 2 children, although it was not clear from the original article (Cheng et al., 2016) what treatment 
modality or disease subtype these children had, including whether or not these were the 2 children with PGA who were treated 
with dapsone. 
Side effects reported following treatment with antibiotics  
Side effects reported included headache and weakness in patients treated with dapsone, gastrointestinal disturbance in a patient 
treated with doxycycline, and insomnia and body fluid discolouration in patients treated with ROM. These adverse effects led to 
discontinuation of dapsone and doxycycline but not ROM treatment in the respective patient groups, although no inferences can be 
made regarding the statistical significance of this (Tables 1 and 2). Of note, all side effects were reported in adults with no side 
effects to antibiotic treatment reported in children. 
Discussion 
GGA does not have a universally recognised gold standard treatment. Indeed, many of the subjects in the articles reviewed 
had failed one or more treatment modalities before being commenced on a trial of antibiotic therapy. This is consistent with the 
findings of Lukacs et al. (2015) looking at various treatment modalities for GGA, with no conclusive evidence that one treatment 
is more effective than the other. Similarly, there is no single recommended treatment modality for GGA in children, albeit GGA is 
uncommon in this patient population. Given the antecedent side effects of other treatments, it is not surprising that antibiotics are 
gaining acceptance in the treatment of GGA. 
Among the articles reporting antibiotic use in GA, we observed that dapsone was the most efficacious treatment modality, 
followed by ROM combination therapy. Only a small number of articles reported on monotherapy with doxycycline/minocycline. 
Dapsone has the ability to suppress non-specific inflammatory changes, hence its wide use in a number of dermatological 
conditions, and particularly its success in the management of GGA (Hoxtermann et al., 1998; Wollina, 2008). Each of the 3 main 
types of antibiotic therapies (ROM vs doxycycline vs dapsone) appears to be largely effective at inducing at least partial remission 
in GGA lesions, with few reports of initial (primary) treatment failure, although, this could be secondary to publication bias rather 
than a true reflection of the efficacy of antibiotic treatment. Disease relapse was noted in a small number of patients treated with 
dapsone and ROM. In these patients, where reported, next-line treatment options included adalimumab, calcitriol, pentoxifylline, 
methotrexate and fluocinomide ointment. While it is not possible to recommend one antibiotic choice over another on the basis of 
our current findings, combination therapy with ROM appears to be the best tolerated by subjects with none of the reported side 
effects leading to discontinuation of treatment. From observational studies to date, ROM therapy appears to have shown promise 
in small open-label prospective trials and may, therefore, warrant further studies with larger, randomised, controlled trials to 
determine if this may, in future, be a potential treatment modality recommended for the management of GGA.  
Our results showed the potential strengths of combining outcomes of rare events through a systematic review of the literature. 
However, these findings should be interpreted with caution, as it is most likely that we might have under-estimated the number of 
cases of GGA due to slight differences in author definitions and regional differences in what constitutes GGA. For example, 
Simpson et al. (2014) appeared to target patients with disseminated GA but their selection criteria for treatment was patients with 
more than 5 GA lesions, which does not qualify as GGA as per the American definition of at least 10 lesions. Subjects in this 
article have, therefore, not contributed towards our overall count and analysis of patients with GGA, but rather have been 
classified as ‘Other/unknown GA subtype’. Furthermore, not all of the studies included stated if histopathological confirmation of 
the diagnosis of GA had been sought, and, therefore, classification relied on authors’ descriptions of the lesions. 
In addition, the lack of robust studies such as randomised controlled trials was a significant limitation, and none of the literature 
looking at ROM combination therapy was in children.  The paucity of evidence to support the use of antibiotics in the treatment of 
GGA in children is further hampered by tetracycline and, in some regions, the quinolones not being licensed for use in children. 
Given that GA often resolves spontaneously without treatment, albeit this may take many years and it is not possible to predict a 
time frame by which the disease could resolve, conservative management may be an appropriate course of action. Ultimately, 
until there is good quality evidence to recommend any specific treatment modality, it is necessary to exercise clinical judgment 
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and weigh up the risks and benefits of different treatment options versus conservative management on a case-by-case basis while 
taking into consideration the individual needs of the patient when determining the best management plan for the patient.
Conclusion 
This review demonstrates that dapsone is currently the most frequently used single antibiotic in the treatment of GGA in 
children. Although ROM has shown some promising results in adults, there is paucity of evidence to support its use in the 
treatment of GGA in children, and more studies are therefore needed to validate these findings. 
Conflicts of interest: The authors declare that they have no competing interest 
Funding/Support 
No external funding was received for the design and conduct of this study, nor for the collection, management, analysis, 
interpretation of the data; and preparation, review, or approval of the manuscript; and   decision to submit the manuscript for 
publication. 
Authors’ contributions
GC reviewed the literature, analysed the data, was involved in the interpretation of the data and writing the report (including 
the first draft), co-ordinated the production of the manuscript, had full access to all the data in the study and takes responsibility 
for the integrity of the data and the accuracy of the data analysis, and approved the final manuscript as submitted. LA carried out 
the initial analyses, was involved in the interpretation of the data and writing the report, and approved the final manuscript as 
submitted. GO conceptualised and designed the study, was involved in the interpretation of the data and writing the report, 
co-ordinated the production of the manuscript, had full access to all the data in the study and takes responsibility for the integrity 
of the data and the accuracy of the data analysis and approved the final manuscript as submitted. All authors approved the final 
manuscript as submitted and agree to be accountable for all aspects of the work. 
References 
1. Boyd, A. S. (2012). Granuloma annulare responsive to oral calcitriol. International Journal of Dermatology, 51(1): 120-122.  
2. Brey, N., Malone, J., and Callen, J. P. (2006). Acute-onset, painful acral granuloma annulare: A report of 4 cases and a 
discussion of the clinical and histologic spectrum of the disease. Archives of Dermatology, 142(1), 49-54.  
3. Cheng, Y., Tsai, W., Chuang, F., Chern, E., Lee, C., Sung, C., and  Ho, J. (2016). A retrospective analysis of 44 patients 
with granuloma annulare during an 11-year period from a tertiary medical center in south Taiwan. Dermatologica Sinica, 
34(3), 121-125.  
4. Cyr, P. R. (2006). Diagnosis and management of granuloma annulare. American Family Physician, 74(10), 1729-1734.  
5. Duarte, A., Mota, A., Pereira, M., Baudrier, T., and Azevedo, F. (2009). Generalized granuloma annulare – response to 
doxycycline. Journal of the European Academy of Dermatology and Venereology, 23(1), 84-85.  
6. Garg, S., and Baveja, S. (2013). Generalized granuloma annulare treated with monthly rifampicin, ofloxacin, and minocycline 
combination therapy. Indian Journal of Dermatology, 58(3), 197-199.  
7. Garg, S., and Baveja, S. (2015). Monthly rifampicin, ofloxacin, and minocycline therapy for generalized and localized 
granuloma annulare. Indian Journal of Dermatology, Venereology and Leprology, 81(1), 35-39.  
8. Gualco, F., Zaccaria, E., Drago, F., and Rebora, A. (2007). Interstitial granuloma annulare and borreliosis: A new case.
Journal of the European Academy of Dermatology and Venereology, 21(8), 1117-1118.  
9. Hoxtermann, S., Nuchel, C., and Altmeyer, P. (1998). Fumaric acid esters suppress peripheral CD4- and CD8-positive 
lymphocytes in psoriasis. Dermatology (Basel, Switzerland), 196(2), 223-230.  
10. Kiremitci, U., Karagulle, S., Topcu, E., Gurel, M. S., Erdogan, S. S., Erdemir, A. T., Alyanak, A., and Demirkesen, C. (2006). 
Generalized granuloma annulare resolving to anetoderma. Dermatology Online Journal, 12(7);16. 
11. Kovich, O., and Burgin, S. (2005). Generalized granuloma annulare. Dermatology Online Journal, 11(4);23. 
12. Kozic, H., and Webster, G. F. (2011). Treatment of widespread granuloma annulare with adalimumab: A case report. The 
Journal of Clinical and Aesthetic Dermatology, 4(11), 42-43.  
13. Lukács, J., Schliemann, S., and Elsner, P. (2015). Treatment of generalized granuloma annulare – a systematic review.
Journal of the European Academy of Dermatology and Venereology, 29(8), 1467-1480.  
14. Mahmood, T., Mansouri, B., and Menter, A. (2015). Successful treatment of generalized granuloma annulare with 
adalimumab. Clinical and Experimental Dermatology, 40(5), 537-539.  
15. Marcus, D. V., Mahmoud, B. H., and Hamzavi, I. H. (2009). Granuloma annulare treated with rifampin, ofloxacin, and 
minocycline combination therapy. Archives of Dermatology, 145(7), 787-789.  
16. Martín-Sáez, E., Fernández-Guarino, M., Carrillo-Gijón, R., Muñoz-Zato, E., and Jaén-Olasolo, P. (2008). Efficacy of 
dapsone in disseminated granuloma annulare: A case report and review of the literature. Actas Dermosifiliogr, 99, 64-8.  
12 
17. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., and PRISMA Group. (2009). Preferred reporting items for systematic 
reviews and meta-analyses: The PRISMA statement. Annals of i Internal Medicine, 154(4), 264-269.,  
18. Muhlbauer, J. E. (1980). Granuloma annulare. Journal of the American Academy of Dermatology, 3(3), 217-230. 
19. Piette, E. W., and Rosenbach, M. (2016). Granuloma annulare: Clinical and histologic variants, epidemiology, and genetics. 
Journal of the American Academy of Dermatology, 75(3), 457-465.  
20. Saied, N., Schwartz, R. A., and Estes, S. A. (1980). Treatment of generalized granuloma annulare with dapsone. Archives of 
Dermatology, 116(12), 1345-1346.  
21. Shelley, W. B., and Shelley, E. D. (2001). Granuloma annulare. Advanced dermatologic therapy (2nd ed., pp. 491-498). 
Philadelphia: W. B. Saunders. 
22. Simpson, B., Foster, S., Ku, J. H., Simpson, E. L., and Ehst, B. D. (2014). Triple antibiotic combination therapy may improve 
but not resolve granuloma annulare. Dermatologic Therapy, 27(6), 343-347.  
23. Steiner, A., Pehamberger, H., and Wolff, K. (1985). Sulfone treatment of granuloma annulare. Journal of the American 
Academy of Dermatology, 13(6), 1004-1008.  
24. Thornsberry, L. A., and  English, J. C. (2013). Etiology, diagnosis, and therapeutic management of granuloma annulare: an 
update. American Journal of Clinical Dermatology, 14(4), 279-290.  
25. Villahermosa, L. G., Fajardo, T. T.,Jr, Abalos, R. M., Cellona, R. V., Balagon, M. V., Dela Cruz, E. C., . . .and Walsh, D. S. 
(2004). Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of world health 
organization multi-drug therapy for multi-bacillary leprosy. The American Journal of Tropical Medicine and Hygiene, 70(2), 
197-200.  
26. Wollina, U. (2008). Granuloma annulare disseminatum responding to fumaric acid esters. Dermatology Online Journal, 
14(12).  
27. Yun, J. H., Lee, J. Y., Kim, M. K., Seo, Y. J., Kim, M. H., Cho, K. H. and Yoon, T. Y. (2009). Clinical and pathological 
features of generalized granuloma annulare with their correlation: A retrospective multicenter study in korea. Annals of 
Dermatology, 21(2), 113-119.  
